AAAAAA

   
Results: 1-8 |
Results: 8
SAFETY AND IMMUNOGENICITY OF A CANDIDATE THERAPEUTIC VACCINE, P24 VIRUS-LIKE PARTICLE, COMBINED WITH ZIDOVUDINE, IN ASYMPTOMATIC SUBJECTS
Authors: KELLEHER AD ROGGENSACK M JARAMILLO AB SMITH DE WALKER A GOW I MCMURCHIE M HARRIS J PATOU G COOPER DA
Citation: Ad. Kelleher et al., SAFETY AND IMMUNOGENICITY OF A CANDIDATE THERAPEUTIC VACCINE, P24 VIRUS-LIKE PARTICLE, COMBINED WITH ZIDOVUDINE, IN ASYMPTOMATIC SUBJECTS, AIDS, 12(2), 1998, pp. 175-182
GAG-SPECIFIC IMMUNE-RESPONSES AFTER IMMUNIZATION WITH P17 P24-TY VIRUS-LIKE PARTICLES IN HIV TYPE 1-SEROPOSITIVE INDIVIDUALS/
Authors: KLEIN MR VEENSTRA J HOLWERDA AM ROOS MTL GOW I PATOU G COUTINHO RA DEWOLF F MIEDEMA F
Citation: Mr. Klein et al., GAG-SPECIFIC IMMUNE-RESPONSES AFTER IMMUNIZATION WITH P17 P24-TY VIRUS-LIKE PARTICLES IN HIV TYPE 1-SEROPOSITIVE INDIVIDUALS/, AIDS research and human retroviruses, 13(5), 1997, pp. 393-399
A PILOT PHASE-II STUDY OF THE SAFETY AND IMMUNOGENICITY OF HIV P17 P24-VLP (P24-VLP) IN ASYMPTOMATIC HIV-SEROPOSITIVE SUBJECTS/
Authors: PETERS BS CHEINGSONGPOPOV R CALLOW D FOXALL R PATOU G HODGKIN K WEBER JN
Citation: Bs. Peters et al., A PILOT PHASE-II STUDY OF THE SAFETY AND IMMUNOGENICITY OF HIV P17 P24-VLP (P24-VLP) IN ASYMPTOMATIC HIV-SEROPOSITIVE SUBJECTS/, The Journal of infection, 35(3), 1997, pp. 231-235
THERAPEUTIC VACCINATION (P24-VLP) OF PATIENTS WITH ADVANCED HIV-1 INFECTION DOES NOT ALTER CD4 DECLINE
Authors: SMITH DE BOAG F COLEBUNDERS R WELLER IVD TCHAMOUROFF S WEBER J GOW I PATOU G COOPER DA
Citation: De. Smith et al., THERAPEUTIC VACCINATION (P24-VLP) OF PATIENTS WITH ADVANCED HIV-1 INFECTION DOES NOT ALTER CD4 DECLINE, AIDS, 10, 1996, pp. 65-65
EFFECT OF THERAPEUTIC VACCINATION (P24-VLP) AND AZT ON IMMUNOLOGICAL MARKERS IN EARLY HIV DISEASE
Authors: KELLEHER AD SMITH DE COOPER DA WALKER A GOW I PATOU G
Citation: Ad. Kelleher et al., EFFECT OF THERAPEUTIC VACCINATION (P24-VLP) AND AZT ON IMMUNOLOGICAL MARKERS IN EARLY HIV DISEASE, AIDS, 10, 1996, pp. 137-137
IMMUNIZATION WITH RECOMBINANT P17 P24-TY VIRUS-LIKE PARTICLES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PERSONS/
Authors: VEENSTRA J WILLIAMS TG COLEBUNDERS R DORRELL L TCHAMOUROFF SE PATOU G LANGE JMA WELLER IVD GOEMAN J UTHAYAKUMAR S GOW IR WEBER JN COUTINHO RA
Citation: J. Veenstra et al., IMMUNIZATION WITH RECOMBINANT P17 P24-TY VIRUS-LIKE PARTICLES IN HUMAN IMMUNODEFICIENCY VIRUS-INFECTED PERSONS/, The Journal of infectious diseases, 174(4), 1996, pp. 862-866
IMMUNOGENICITY OF THE YEAST RECOMBINANT P17 P242-TY VIRUS-LIKE PARTICLES (P24-VLP) IN HEALTHY-VOLUNTEERS/
Authors: WEBER J CHEINSONGPOPOV R CALLOW D ADAMS S PATOU G HODGKIN K MARTIN S
Citation: J. Weber et al., IMMUNOGENICITY OF THE YEAST RECOMBINANT P17 P242-TY VIRUS-LIKE PARTICLES (P24-VLP) IN HEALTHY-VOLUNTEERS/, Vaccine, 13(9), 1995, pp. 831-834
HUMAN PARVOVIRUS INFECTION IN HOMOZYGOUS SICKLE-CELL DISEASE
Authors: SERJEANT GR SERJEANT BE THOMAS PW ANDERSON MJ PATOU G PATTISON JR
Citation: Gr. Serjeant et al., HUMAN PARVOVIRUS INFECTION IN HOMOZYGOUS SICKLE-CELL DISEASE, Lancet, 341(8855), 1993, pp. 1237-1240
Risultati: 1-8 |